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IMPORTANCE One-year outcomes from the Early Venous Reflux Ablation (EVRA) randomized
trial showed accelerated venous leg ulcer healing and greater ulcer-free time for participants
who are treated with early endovenous ablation of lower extremity superficial reflux.
OBJECTIVE To evaluate the clinical and cost-effectiveness of early endovenous ablation of
superficial venous reflux in patients with venous leg ulceration.
DESIGN, SETTING, AND PARTICIPANTS BetweenOctober 24, 2013, and September 27, 2016, the
EVRA randomized clinical trial enrolled 450 participants (450 legs) with venous leg ulceration
of less than 6months’ duration and superficial venous reflux. Initially, 6555 patients were
assessed for eligibility, and 6105 were excluded for reasons including ulcer duration greater
than 6months, healed ulcer by the time of randomization, deep venous occlusive disease,
and insufficient superficial venous reflux to warrant ablation therapy, among others. A total of
426 of 450 participants (94.7%) from the vascular surgery departments of 20 hospitals in the
United Kingdomwere included in the analysis for ulcer recurrence. Surgeons, participants,
and follow-up assessors were not blinded to the treatment group. Data were analyzed from
August 11 to November 4, 2019.
INTERVENTIONS Patients were randomly assigned to receive compression therapy with early
endovenous ablation within 2 weeks of randomization (early intervention, n = 224) or
compression with deferred endovenous treatment of superficial venous reflux (deferred
intervention, n = 226). Endovenous modality and strategy were left to the preference of the
treating clinical team.
MAIN OUTCOMES ANDMEASURES The primary outcome for the extended phase was time to
first ulcer recurrence. Secondary outcomes included ulcer recurrence rate and
cost-effectiveness.
RESULTS The early-intervention group consisted of 224 participants (mean [SD] age, 67.0
[15.5] years; 127 men [56.7%]; 206White participants [92%]). The deferred-intervention
group consisted of 226 participants (mean [SD] age, 68.9 [14.0] years; 120men [53.1%]; 208
White participants [92%]). Of the 426 participants whose leg ulcer had healed, 121 (28.4%)
experienced at least 1 recurrence during follow-up. There was no clear difference in time to
first ulcer recurrence between the 2 groups (hazard ratio, 0.82; 95% CI, 0.57-1.17; P = .28).
Ulcers recurred at a lower rate of 0.11 per person-year in the early-intervention group
compared with 0.16 per person-year in the deferred-intervention group (incidence rate ratio,
0.658; 95% CI, 0.480-0.898; P = .003). Time to ulcer healing was shorter in the
early-intervention group for primary ulcers (hazard ratio, 1.36; 95% CI, 1.12-1.64; P = .002). At
3 years, early intervention was 91.6% likely to be cost-effective at a willingness to pay of
£20000 ($26 283) per quality-adjusted life year and 90.8% likely at a threshold of £35000
($45 995) per quality-adjusted life year.
CONCLUSIONS AND RELEVANCE Early endovenous ablation of superficial venous reflux was
highly likely to be cost-effective over a 3-year horizon compared with deferred intervention.
Early intervention accelerated the healing of venous leg ulcers and reduced the overall
incidence of ulcer recurrence.
TRIAL REGISTRATION ClinicalTrials.gov identifier: ISRCTN02335796
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Published online September 23, 2020.
Invited Commentary
Supplemental content
Author Affiliations:Author
affiliations are listed at the end of this
article.
Group Information: Themembers of
the Early Venous Reflux Ablation Trial
Group are listed at the end of the
article.
Corresponding Author: Alun H.
Davies, DSc, Section of Vascular
Surgery, Department of Surgery &
Cancer, Imperial College London,
4th Floor, East Wing, Charing Cross
Hospital, Fulham Palace Rd,
LondonW6 8RF, United Kingdom
(a.h.davies@imperial.ac.uk).
Research
JAMASurgery | Original Investigation
(Reprinted) E1
Downloaded From: https://jamanetwork.com/ on 10/20/2020
V enous leg ulceration is the most extreme manifesta-tion of chronic venous disease, andworldwide preva-lence is increasing.1,2 Compression therapy has been
shownto improveulcerhealing, and 1-yearoutcomes fromthe
Early Venous Reflux Ablation (EVRA) trial revealed that early
endovenous ablation of superficial venous reflux (varicose
veins) acceleratedhealingof venous legulcers comparedwith
deferred intervention.3,4 Early interventionwas also shown to
becost-effective in theshort term.5 In theEffectof Surgeryand
CompressiononHealing andRecurrence (ESCHAR) study, su-
perficial venous surgery reduced venous ulcer recurrence at
4 years from 56% in participants treated with compression
alone to 31% in the group treated with compression and vari-
coseveinsurgery.6Ulcer recurrence ratesare likely tobehigher
than the 56% in the ESCHAR trial because compression is of-
ten not prescribed and compliance is poor, particularly out-
side clinical trials. Superficial venous surgeryhas largely been
superseded by endovenous ablation procedures (ultrasound-
guided foam sclerotherapy and thermal and nonthermal ab-
lation), but long-term outcomes in patients with venous leg
ulcers are unknown.
Extended follow-upwasperformed for participants in the
EVRA trial to evaluate the influence of early endovenous ab-
lation of superficial venous reflux on outcomes up to 5 years
for participants with venous leg ulcers.
Methods
Study Design and Population
This parallel-group randomized controlled trial was con-
ducted in 20 centers in the United Kingdom (trial protocol in
Supplement 1 and eTable 1 in Supplement 2), where potential
participantswere screened fromOctober 24, 2013, to Septem-
ber 27, 2016. Eligible participants had venous leg ulceration
that had been present for 6 weeks to 6 months in addition to
significant superficial venous reflux as assessed by the treat-
ing clinician. All trial centers had established leg ulcer refer-
ral and treatment pathways andwere able to provide endove-
nous intervention within 2 weeks.
The study design and 1-year outcomes of the EVRA trial
havebeenpublishedpreviously.3,4Extendedfollow-upwasap-
provedby theSouthWest-CentralBristolResearchEthicsCom-
mittee on May 24, 2017. The independent trial steering com-
mittee and independent data and safety monitoring
committeeswere retained toprovideongoingoversight for the
study extension. All patients providedwritten informed con-
sent for long-term follow-up at randomization, and this con-
sent was reaffirmed for all participants contacted for long-
term data collection. The EVRA trial was funded by the UK
National Institute forHealth ResearchHealth TechnologyAs-
sessment Programme, and the funder of the studyhadno role
in design and conduct of the study; collection, management,
analysis, and interpretation of the data; preparation, review,
or approval of the manuscript; or the decision to submit the
manuscript for publication. During protocol development, a
patient focus groupwas used to guide study design, and a pa-
tientwas also included as amember of the trial steering com-
mittee. This study followed theConsolidatedStandardsofRe-
porting Trials (CONSORT) reporting guideline.
Randomization
Participants were assigned randomly in a 1:1 ratio to receive
compression therapyandendovenousablationwithin2weeks
(early-intervention group) or to receive compression therapy
alone with deferred endovenous ablation once the ulcer had
healed, or after 6months if theulcerhadnothealed (deferred-
intervention group). Randomization sequences were created
in advance for each center by a trial statistician, and ran-
domly permuted blocks were used with 2 block sizes. Sur-
geons, participants, and follow-upassessorswerenot blinded
to the treatment group. Photographic verification for healing
ofprimaryulcerationwasperformedbyclinicalexpertsblinded
to treatment allocation.
Procedures
Woundcareandcompressiontherapywereguidedby localpro-
tocols, and multilayer elastic compression (2, 3, or 4 layers),
short-stretchbandaging, andcompressionhosierywere all ac-
cepted. The endovenous treatment was left to the discretion
of the responsible clinical teams,withendovenous thermal ab-
lationmodalities (laseror radiofrequencyablation),ultrasound-
guided foamsclerotherapy, or nonthermal nontumescent en-
dovenous interventions performed alone or in combination.
Decisions regarding treatment of branch varicosities or per-
forators were left to physician choice. EVRA trial centers had
extensive experience inperformingendovenous ablationpro-
cedures. Participants in the early-intervention group under-
went follow-up duplex ultrasound assessment 6 weeks after
endovenous ablation, and additional interventions for super-
ficial venous reflux in either groupwere performed at thedis-
cretionof the treating clinical teams.All participantswere ad-
vised to use compression hosiery after ulcer healing, guided
by local policy; additional duplex ultrasound assessmentwas
not in the study protocol.
Telephone follow-up for all living participants was per-
formed between October 2018 and March 2019 to obtain pri-
mary and secondary end point data. Where possible, partici-
pants in the EVRA trial were reminded at the 12-month visit
to record any recurrent ulcers and health care visits in a par-
ticipant diary to aid in subsequent recall. In the extended-
phase follow-up, participants were asked on the telephone
Key Points
Question In patients with venous leg ulceration and superficial
reflux, what is the clinical and cost-effectiveness of early
endovenous ablation of reflux?
Findings In this 450-patient, multicenter, randomized clinical
trial, early endovenous ablation with compression accelerated
venous ulcer healing, reduced the overall incidence of ulcer
recurrence, and was highly cost-effective compared with
compression with deferred intervention.
Meaning To deliver clinical and cost benefits, leg ulcer care
pathways should be revised to include early assessment and
treatment of superficial venous reflux.
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(using a standardized questionnaire) about ulcer recurrences
(defined as any wound on the study leg) and asked to recall
dates of recurrence, subsequent healing, and details of addi-
tional treatments. Hospital and community clinical records
were reviewed for further verification, and further calls were
made to participants to clarify discrepancies.
A disease-specific quality-of-life assessment (Aberdeen
Varicose Vein Questionnaire) and 2 generic quality-of-life as-
sessments (theEuroQolGroup5-Dimension5-Level question-
naire [EQ-5D-5L] and the Medical Outcomes Study 36-Item
Short-Form Health Survey) (eTable 2 in Supplement 2) were
performed between October 2018 and March 2019 (either on
telephoneor bymail). Adverse eventswere recorded in accor-
dance with Good Clinical Practice guidelines.
Outcome Assessments
Theprimaryoutcome for the extended follow-upphaseof the
studywas time to firstulcer recurrence fromdateofulcerheal-
ing. The 1-year results, with time to ulcer healing as the pri-
mary outcome measure, were reported previously.3,4 Heal-
ing of the primary venous leg ulcer was defined as complete
re-epithelialization of all ulceration on the randomized (ref-
erence) leg with no scab or requirement for dressings, and a
blinded verification process was used to confirm healing.7
The secondary outcomemeasureswere time to first ulcer
recurrence fromdateof randomization, theproportionof par-
ticipantswith recurrentulcerationatdifferent timepoints (ul-
cer recurrence rate), time tohealing of index and recurrent ul-
cers, lengthof timefree fromulcers fromrandomizationto final
follow-up (ulcer-free time), recurrent ulcer incidence rate and
incidence rate ratio, participant-reportedhealth-relatedqual-
ity of life, and cost-effectiveness.
Statistical Analysis
Statistical analyses of the data were performed from August
11, 2019, to November 4, 2019. The trial was designed to de-
tecta 15%absolutedifference inulcer-healing ratesat24weeks
(assuming a60%rate of ulcer healing inparticipants random-
ized to compression alone) with 90% power and 2-sided al-
pha level of 5%.Assuming90%of theparticipants in theEVRA
trial would achieve ulcer healing and 15% losses to follow-up,
death, or withdrawal from the study, we estimated that 344
participants would be available for analysis of ulcer recur-
rence.For extended follow-upanalysis,wecalculated that this
was sufficient to detect a 15% difference in ulcer recurrence
(30% in the early-intervention group vs 45% in the deferred-
interventiongroup)with82%poweror a 20%difference inul-
cer recurrence (30% in the early-intervention group and 50%
in the deferred-intervention group) with 97% power.
Thenull hypothesiswas that there is nodifference in time
toulcer recurrence between the early-intervention group and
thedeferred-interventiongroup.Thiswas testedusingCox re-
gression with center as a random effect and participant age,
ulcer size, and chronicity as fixed effects.WeusedCox regres-
sion, adjusted asmentioned, to test for differences in time to
healing of primary ulcer and recurrent ulcers. Ulcer recur-
rence rates (unadjusted)were calculatedat annual timepoints
up to 4 years with 95% CIs using the Kaplan-Meier method.8
Moreover, the incidence rateof recurrentulcers (ulcersperper-
son-years) and incidence rate ratioswith 95%CIswere calcu-
lated. Ulcer-free timewas defined as the total number of days
that the reference leg remained healed during the entire fol-
low-up period. We used a Cox regression model adjusted for
center, patient age, ulcer size, and ulcer chronicity, as men-
tioned, as well as length of follow-up (as a fixed effect) to test
the hypothesis that therewas no difference in ulcer-free time
between the early-intervention and deferred-intervention
groups. Participantswhodid not consent to the extended fol-
low-up are included to 12 months only. Adverse events were
recorded.
Differencesbetweenstudygroups to1year foreachquality-
of-life measure have been published previously.3 We used
3-levelmixedmodels to assess differences in each quality-of-
lifemeasurebetweenthe2 treatmentgroups.All analyseswere
performed on intention-to-treat. Participants whose primary
ulcer did not heal were not eligible for analysis for ulcer re-
currence, but were included in all other secondary analyses.
Therewereno statistical adjustments formultiple testing.We
performedper-protocol analyses for time toulcer healing and
time to first ulcer recurrence, and statistical significance was
set at 5%.
Health Economic Analysis
We performed an in-trial health economic evaluation and es-
timated costs andquality-adjusted life years (QALYs) from the
perspectiveof theUKNationalHealthServiceandPersonal So-
cial Services over a 3-year timehorizon. Results to 1 year have
beenpublishedpreviously.5Thepriceyearwas the2017 to2018
period. Discounting was applied according to UK Govern-
mentguidelines (3.5%peryear forcostsandhealthoutcomes).9
Study conduct and reporting complied with current guide-
lines for economic evaluation.10 We collected details of re-
source use in hospital and community care related to venous
leg ulcer treatment, adverse events, or complications of ve-
nous leg ulcers or treatments. We used case note review and
questionnaires completed at baseline and monthly thereaf-
ter to 1 year, plus 1 further telephone follow-up between Oc-
tober 2018 and March 2019, with notes review for additional
verification. Each itemof resource usewasmultiplied by unit
costs obtained from published literature,11 national unit
costs,12,13 and manufacturers’ list prices to calculate overall
costs for each participant (eTable 3 in Supplement 2).
The EQ-5D-5L was completed at baseline, 6 weeks, 6
months, 12months, and 1 further follow-up betweenOctober
2018andMarch2019.Utility indices foreach individual at each
follow-up timewere calculated from the EQ-5D-5L question-
naire using the tariff recommended by the National Institute
forHealthandCareExcellence.14Cost andEQ-5D-5Ldatawere
analyzed usingmixedmodels and total mean costs, and total
meanQALYswere estimated for the 3-year timehorizon. Sen-
sitivityanalysesusedanalternative tariff for theEQ-5D-5L,per-
protocol analysis and 4- and 5-year time horizons.15 Uncer-
tainty in mean costs and QALYs was quantified using
bootstrapping andpresentedusing cost-effectiveness accept-
ability curves (full description in eMethods and eTable 3 of
Supplement 2).
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Results
Patients
FromOctober 24, 2013, through September 27, 2016, we ran-
domly assigned 450 participants to undergo early interven-
tion (224 participants) or deferred intervention (226 partici-
pants) in addition to compression therapy. The early-
intervention group consisted of 224 participants (mean [SD]
age, 67.0 [15.5] years; 127men [56.7%] and97women [43.3%];
206 White participants [92%]). The deferred-intervention
groupconsistedof226participants (mean [SD]age,68.9 [14.0]
years; 120 men [53.1%] and 106 women [46.9%]; 208 White
participants [92%]) (Table 1).3,4 Of 224 participants random-
ized to early intervention, 203 (90.6%) underwent endove-
nous ablation within 2 weeks of randomization. Of 226 par-
ticipants in thedeferred-intervention group, 171 (75.6%)were
treatedwith endovenous ablationwithin 12months (Table 1).
The final telephone follow-up was completed on March 28,
2019.
Datawere collected over the telephone and frommedical
notes or frommedical notes alone for 399 of 422 participants
(94.5%) still participating at 1 year (Figure 1). Median fol-
low-up period from randomizationwas 1286 days (interquar-
tile range [IQR], 1038-1531days) in theearly-interventiongroup
and 1287 days (IQR, 1063-1519 days) in the deferred-
interventiongroup.Mortalitywassimilarbetweenthe2groups,
and no participants died as a result of intervention (eFigure 1
in Supplement 2).
Ulcer Recurrence
Of the426participantswhose legulcerhadhealed, 121 (28.4%)
experienced at least 1 recurrence. There were 175 episodes of
recurrent ulceration during follow-up (72 in the early-
intervention group [56 participants]; 103 in the deferred-
intervention group [65 participants]).
Time to first recurrence from ulcer healing (adjusted for
participant age, ulcer size, andulcer chronicity)was similar in
the early-intervention group and the deferred-intervention
group (hazard ratio [HR] for ulcer recurrence, 0.82; 95% CI,
0.57-1.17;P = .28) (Figure 2A). Calculating time toulcer recur-
rence from randomization rather than date of healing did not
affect these findings (HR, 0.86; 95% CI, 0.60-1.24; P = .43)
(eFigure 2 in Supplement 2). Ulcer recurrence rates (from ul-
cer healing) at 4 years were 34.6% (95%CI, 26.7%-44.0%) for
the early-intervention group and 38.4% (95% CI, 30.8%-
47.2%) for the deferred-intervention group (Table 2). In the
early-interventiongroup, 72 recurrentulcersoccurred in675.5
years of follow-up after healing of the primary ulcer com-
paredwith 103 ulcers in the deferred-intervention groupdur-
ing 636.0 years of follow-up. Therefore, ulcers recurred at a
rateof0.11perperson-year in theearly-interventiongroupand
0.16 per person-year in the deferred-intervention group (in-
cidence rate ratio, 0.658; 95% CI, 0.480-0.898, P = .003).
Secondary Outcomes
Time to ulcer healing of the primary ulcer was shorter in
the early-intervention group compared with the deferred-
Table 1. Baseline Characteristics and Details of Interventions Performed
Characteristic
No. (%)a
Early intervention
(n = 224)
Deferred intervention
(n = 226)
Age, mean (SD), y 67.0 (15.5) 68.9 (14.0)
Sex
Women 97 (43.3) 106 (46.9)
Men 127 (56.7) 120 (53.1)
Body mass index, mean (SD)b 30.1 (7.8)
[n = 218]
30.4 (7.4) [n = 219]
Race/ethnicity
White 206 (92.0) 208 (92.0)
Otherc 18 (8.0) 18 (8.0)
History of DVTd 15 (6.7) 15 (6.6)
Diabetes 34 (15.2) 28 (12.4)
Previous leg ulcerationd 118 (52.7) 117 (52.0) [n = 225]
Ulcer chronicity,
median (IQR), moe
3.2 (2.3-4.2) 3.0 (1.7-4.2)
Trial leg
Right 107 (47.8) 115 (50.9)
Left 117 (52.2) 111 (49.1)
Ulcer size,f median (IQR), cm2 2.4 (1.0-7.1) 2.9 (1.1-8.2)
Presence of deep refluxd,g 74 (33.0) 69 (30.5)
Pattern of superficial reflux
at baselined
GSV reflux alone 123 (54.9) 125 (55.4)
SSV reflux alone 25 (11.2) 30 (13.3)
GSV and SSV reflux 65 (29.0) 56 (24.8)
Other pattern of reflux 11 (4.9) 15 (6.6)
Timing of first endovenous
treatment, from randomization
Within 2 wk 203 (90.6) 1 (0.4)
Between 2 wk and 12 moh 15 (6.7) 170 (75.2)
After 12 mo 0 (0.0) 8 (3.5)
No treatmenti 6 (2.7) 47 (20.8)
Total No. of procedures 283 227
No. of procedures per participant
1 164 144
2 43 23
3 11 11
4 0 1
Abbreviations: DVT, deep vein thrombosis; GSV, great saphenous vein; IQR,
interquartile range; SSV, small saphenous vein.
a Values are presented as No. (%) for categorical variables andmean (SD) for
continuous variables unless otherwise specified.
b Calculated as weight in kilograms divided by height in meters squared.
c Early-intervention group: Asian, 11; Black, 3; and other, 4; deferred-
intervention group: Asian, 12; Black, 5; and other, 1.
d In randomized leg.
e As reported by participant.
f Ulcer size evaluated using digital planimetry from standardized digital
photographs by assessor blinded to intervention group.
g Defined as presence of retrograde flow in common femoral, femoral, or
popliteal veins of >1-second duration after augmentation.
h Further details of timings of interventions have been published previously.3,4
i Reasons for no treatment in the deferred-intervention group were patient
choice (16 of 47), patient died (7 of 47), withdrawal from study (7 of 47), lost
to follow-up (5 of 47), clinician decision (3 of 47), and reason not recorded (9
of 47).
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intervention group (HR, 1.36; 95% CI, 1.12-1.64, P = .002)
(Figure 2B). Unlike the 1-year healing outcomes published
previously,3,4 this analysis also included primary ulcers that
healed after 12months. There was no clear difference in time
to healing of recurrent ulcers between the early-intervention
groupand thedeferred-interventiongroup (HR for healing in-
cluding all ulcer recurrences, 1.10; 95% CI, 0.79-1.54; P = .58;
eFigure 3 in Supplement 2) (HR for healing of first recur-
rence, 0.91; 95% CI, 0.62-1.35; P = .64).
The median ulcer-free time was 1137 days (IQR, 860-1411
days) in theearly-interventiongroupand 1090days (IQR,625-
1364 days) in the deferred-intervention group. Adjusting for
follow-up period, participant age, ulcer size, and ulcer chro-
nicity, there was no difference between the groups (HR for
greater ulcer-free time, 0.84; 95%CI, 0.69-1.02;P = .07). Pre-
specifiedper-protocol analysesarepresented ineFigures4and
5 in Supplement 2. During extended follow-up, the Aberdeen
VaricoseVeinQuestionnaire,EQ-5D-5L, and the36-ItemShort-
Form Health Survey domains were similar between the 2
groups (eTable 4 in Supplement 2).
Health Economic Analysis
Full details of resource use and costs for the 2 groups are pre-
sentedineTables5and6inSupplement2.Discountedtotalmean
costof early interventionwas –£155 (95%CI, –£1262 to£953) ($–
213 [95%CI, –$1654to$1249])comparedwithdeferred interven-
tionperparticipantover3years (Figure3;andeTable7 inSupple-
ment 2), indicating that early interventionwas, on average, the
less costly strategy. Participants randomized to early interven-
tionexperienced,onaverage,greaterQALYsafter3years (mean
Figure 1. Consort Diagram Showing Enrollment, Allocation, 1-Year, and Extended Follow-Up
6555 Patients assessed for eligibility
6105 Excluded
1772 Had ulcer duration >6 mo
873 Had ABI <0.8 or arterial ulcer or both
610 Had ulcer healed by the time of randomization
568 Did not have ulcer
496 Withdrawn by clinician
434 Declined to participate
393 Had other type of ulcer: dermatologic, diabetic
foot, or mixed
378 Did not have venous disease
267 Had insufficient superficial venous reflux to
warrant ablation
199 Deep venous occlusive disease
71 Unable to provide consent
35 Unable to adhere to compression therapy
9 Had other reason
450 Randomized
208 Included in intention-to-treat analysis
for time to ulcer recurrence
218 Included in intention-to-treat analysis
for time to ulcer recurrence
3-5 y
8 Patients died
7 Lost to follow-up
10 Telephone follow-up
30 Medical records review
160 Telephone and medical records review
3-5 y
1 Patient withdrew from the study
10 Patients died
16 Lost to follow-up
11 Telephone follow-up
26 Medical records review
162 Telephone and medical records review
12 mo
10 Patients withdrew from study
8 Patients died
5 Lost to follow-up
12 mo
1 Patient did not adhere to protocol
5 Patients withdrew from study
4 Patients died
10 Lost to follow-up
226 Randomized to deferred-intervention group 224 Randomized to early-intervention group
422 To be contacted for extended follow-up
ABI indicates ankle-brachial index.
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difference inQALY,0.073; 95%CI, –0.06 to0.20) using theEQ-
5D-5L tariff recommendedbyNational Institute forHealth and
Care Excellence. Early intervention was therefore a dominant
strategy,with lowermean cost andgreatermeanQALYbenefit.
Findings were similar for 4-year and 5-year horizons (eTable 7
in Supplement 2) and with a per-protocol analysis (eTable 8 in
Supplement 2), although the difference inQALYwas smaller at
3 years using an alternative tariff for EQ-5D-5L (eTable 7 in
Supplement 2). Analysis using bootstrap simulations demon-
strated that early intervention was 91.6% likely to be cost-
effectiveatawillingness-to-pay thresholdof£20000($26283)
per QALY and 90.8% at a threshold of £35000 ($45995) (eFig-
ures 6 and 7 in Supplement 2).
Discussion
One-year results from the EVRA trial showed that early abla-
tion of superficial venous reflux accelerated healing of venous
leg ulcers.3,4 Longer-term follow-up in this study demon-
strated that fewer recurrent ulcers per year of follow-up oc-
curred in theearly-interventiongroup, even though the time to
firstulcerrecurrencedidnotdifferbetweenthegroups.Thetotal
meancostswere lower in theearly-interventiongroup,andpar-
ticipants reportedhigherQALYs, indicating that early interven-
tion is highly likely to be cost-effective irrespective of the will-
ingness-to-pay threshold used by the health care system.
Ultrasound-guided foam sclerotherapywas themost com-
monendovenous treatment in this trial, andsomestudieshave
reportedhighratesof technical failurecomparedwithotheren-
dovenousmodalitiesoropenvaricoseveinsurgery.11,16The4-year
Figure 2. Kaplan-Meier Curves for Time to Primary Ulcer Recurrence and Ulcer Healing in Early-Intervention and Deferred-Intervention Groups
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Table 2. Ulcer Recurrence Rates in Early-Intervention and Deferred-Intervention Groups
Study group Follow-up, y No.a Recurrences
Cumulative
recurrence rate, % 95% CI
Early-intervention group 1 162 28 13.48 9.51-18.94
2 150 7 17.28 12.71-23.26
3 102 12 24.56 18.99-31.41
4 32 8 34.6 26.7-44.04
5 1 1 NA NA
Deferred-intervention group 1 154 38 18.98 14.18-25.13
2 132 9 23.9 18.52-30.53
3 93 10 29.95 23.92-37.1
4 32 8 38.42 30.81-47.18
5 1 0 NA NA
Abbreviation: NA, not available.
a Number of participants successfully
followed up for ulcer recurrence at
each time period
postrandomization.
Figure 3. Mean Cost Per Participant at 3 Years
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ulcer recurrencerates in this trialarecomparable to thoseofpre-
viousstudiesevaluatingulcerrecurrenceafteropenvaricosevein
surgery,andoutcomesinbothgroupsoftheEVRAtrialarefavor-
ablecomparedwithoutcomeswithcompressionalone.6,17These
findings support the strategy adopted in this study, where the
choice of endovenousmodalitywas left to thediscretionof the
treating clinician. Ablating superficial venous reflux is likely to
bemore important than the choice ofmodality.
Strengths and Limitations
The health economic benefits of early intervention demon-
stratedinthis trialareparticularlycompellingbecausetheprem-
ise of a less costly treatment strategy that offersmore QALYs is
an important driver for change in behavior irrespective of the
countryorhealthcaresystem.Themethodof follow-upisa limi-
tationof this study, asonly telephone follow-upat a single time
pointafter 1yearwaspossibleowingtofunding limitations;pho-
tographicassessmentwasnotdeemedfeasible.However,most
participants in this trialwerekeptunder regular surveillanceby
recruitingcentersaspartofnormal clinical care, resulting inac-
curately recordedoutcomedata.One-fifthof theparticipants in
the deferred-intervention group did not undergo endovenous
intervention at all. It is difficult to predictwhether clinical out-
comeswouldhavebeenbetter ifallparticipantshadbeentreated,
but delaying intervention was associated with fewer partici-
pantsundergoingendovenousablation.Theresultsof thisstudy
reinforcetheconclusionsfromthe1-yearEVRAresults, thatearly
endovenous ablationof superficial venous reflux is highlyben-
eficial forbothpatientsandhealthcareprofessionals.Theseob-
servations indicate that apolicyofdeferredordelayedendove-
nous interventionis illogical forpatientswithvenousulceration.
Long-termoutcomesbeyond4years remainunknown.Be-
cause chronic venoushypertension ismultifactorial, ulcer re-
currence is likely tobe a commonevent in this population, de-
spite endovenous ablation. Thirty percent of participants
recruited to theEVRAtrial suffered recurrentulcersduring fol-
low-up.Aggressive investigationand treatmentofvenousout-
flowobstruction have been advocated, and the use of venous
stents to correctnonthrombotic andpost-thromboticdeepve-
nous occlusive disease is increasing in popularity but re-
quires robust evaluation.18,19 Although theremaybe a role for
deep vein stenting in some patients with venous ulceration,
excellenthealingoutcomeswereachieved in theEVRAtrial co-
hort with combined good compression therapy and superfi-
cial venous ablation. It should alsobenoted that patientswith
concomitantarterialdisease, footulceration,or thosenot com-
pliant with compression were not included.
Conclusion
In this randomized clinical trial, early endovenous ablation of
superficialvenousreflux inadditiontocompressiontherapyre-
ducedtimetoulcerhealing forprimaryulcers.Wefoundnosta-
tistical evidence that early endovenous ablation reduces time
to first ulcer recurrence, but it was associated with a reduced
incidence rateof recurrentulcers and ishighly likely tobecost-
effective in themanagement of venous leg ulceration.
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